Braeburn Pharmaceuticals said last week that it named Michael Derkacz as president and CEO of the buprenorphine implant-maker. Most recently, Derkacz worked as senior VP and head of global central nervous system and pain therapeutic areas for Teva Pharmaceuticals (NYSE:TEVA).
Behshad Sheldon, who helped to found Braeburn in 2012, is slated to step down from Braeburn as president & CEO effective immediately, but will remain on as a consultant.
“Mike is an accomplished and highly successful commercial leader, with deep expertise in launching new products, creating highly effective teams, and focused organizational leadership,” chairman Dr. Seth Harrison said in prepared remarks. “We welcome Mike to Braeburn at this important moment in the Company’s growth, as we drive commercial efforts for our first approved product and finalize regulatory filings seeking approval of our flagship opportunity, CAM2038.”